Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1995 1
1997 1
1998 1
1999 1
2002 4
2003 1
2004 1
2005 1
2008 1
2009 2
2010 11
2011 8
2012 11
2013 23
2014 18
2015 12
2016 14
2017 11
2018 10
2019 17
2020 19
2021 23
2022 15
2023 17
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

201 results

Results by year

Filters applied: . Clear all
Page 1
Long-term oral blonanserin treatment for schizophrenia: a review of Japanese long-term studies.
Murasaki M, Inoue Y, Nakamura H, Kinoshita T. Murasaki M, et al. Ann Gen Psychiatry. 2021 Sep 7;20(1):41. doi: 10.1186/s12991-021-00361-3. Ann Gen Psychiatry. 2021. PMID: 34493318 Free PMC article. Review.
Based on the clinical symptoms at baseline, the physician determined the treatment: blonanserin monotherapy, blonanserin in combination with the existing antipsychotic medication, or therapy simplified to haloperidol together with blonanserin. ...Blonanser …
Based on the clinical symptoms at baseline, the physician determined the treatment: blonanserin monotherapy, blonanserin in co …
Comparative study of 2-(4-ethyl-1-piperazinyl)-4-(fluorophenyl)-5,6,7,8,9, 10-hexahydrocycloocta[b]pyridine (AD-5423) and haloperidol for their pharmacological activities related to antipsychotic efficacy and/or adverse side-effects.
Noda Y, Kurumiya S, Miura Y, Oka M. Noda Y, et al. J Pharmacol Exp Ther. 1993 May;265(2):745-51. J Pharmacol Exp Ther. 1993. PMID: 8098763
In these tests, AD-5423 was quite similar to haloperidol in potencies and time-course patterns of the effects. However, different results were obtained between the effects of AD-5423 and haloperidol in possible animal models of tardive dyskinesia and m …
In these tests, AD-5423 was quite similar to haloperidol in potencies and time-course patterns of the effects. However, differ …
Effect of Blonanserin on the Proliferation and Migration of Glioblastoma Cells.
Tsuchiya N, Okamoto K, Nakao S, Ohmori S, Shimizu T. Tsuchiya N, et al. Pharmazie. 2023 May 1;78(5):37-41. doi: 10.1691/ph.2023.1821. Pharmazie. 2023. PMID: 37189270
Blonanserin showed growth inhibitory activity without D2 antagonism following an independent competition analysis using blonanserin and D2 antagonists. When the anti-migration activity of U251 cells was measured, blonanserin was found to attenuate cell migrat …
Blonanserin showed growth inhibitory activity without D2 antagonism following an independent competition analysis using blonanseri …
Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials.
Kishi T, Matsuda Y, Nakamura H, Iwata N. Kishi T, et al. J Psychiatr Res. 2013 Feb;47(2):149-54. doi: 10.1016/j.jpsychires.2012.10.011. Epub 2012 Nov 3. J Psychiatr Res. 2013. PMID: 23131856 Review.
While dizziness (RR = 0.47, CI = 0.23-0.93, NNH = not significant) and akathisia (RR = 0.54, CI = 0.32-0.90, NNH = 7) occurred significantly less often with blonanserin than with haloperidol, blonanserin had a 1.62 higher risk of akathisia than risperidone (CI = 1.1 …
While dizziness (RR = 0.47, CI = 0.23-0.93, NNH = not significant) and akathisia (RR = 0.54, CI = 0.32-0.90, NNH = 7) occurred significantly …
Blonanserin. AD 5423.
[No authors listed] [No authors listed] Drugs R D. 2002;3(6):405-6. doi: 10.2165/00126839-200203060-00009. Drugs R D. 2002. PMID: 12516946 No abstract available.
Blonanserin: a review of its use in the management of schizophrenia.
Deeks ED, Keating GM. Deeks ED, et al. CNS Drugs. 2010 Jan;24(1):65-84. doi: 10.2165/11202620-000000000-00000. CNS Drugs. 2010. PMID: 20030420 Review.
Oral blonanserin (Lonasen) is an atypical antipsychotic agent indicated for use in patients with schizophrenia in Japan and Korea. ...Blonanserin is generally well tolerated and appears to have an acceptable profile in terms of bodyweight gain. ...
Oral blonanserin (Lonasen) is an atypical antipsychotic agent indicated for use in patients with schizophrenia in Japan and Korea. .. …
Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study.
Iwata N, Ishigooka J, Kim WH, Yoon BH, Lin SK, Sulaiman AH, Cosca R, Wang L, Suchkov Y, Agarkov A, Watabe K, Matsui T, Sato T, Inoue Y, Higuchi T, Correll CU, Kane JM. Iwata N, et al. Schizophr Res. 2020 Jan;215:408-415. doi: 10.1016/j.schres.2019.07.055. Epub 2019 Aug 27. Schizophr Res. 2020. PMID: 31471246 Free article. Clinical Trial.
BACKGROUND: Blonanserin is a second-generation antipsychotic used for the treatment of schizophrenia. ...Compared with placebo, blonanserin significantly improved PANSS total scores at 6 weeks (least square mean [LSM] difference vs placebo: -5.6 with blonanserin …
BACKGROUND: Blonanserin is a second-generation antipsychotic used for the treatment of schizophrenia. ...Compared with placebo, bl …
[Blonanserin in the treatment of schizophrenia].
Tenjin T, Miyamoto S. Tenjin T, et al. Nihon Rinsho. 2013 Apr;71(4):660-5. Nihon Rinsho. 2013. PMID: 23678596 Review. Japanese.
Blonanserin was developed in Japan in 2008 as an antipsychotic drug. ...Taken together, blonanserin may be a promising candidate for a first-line antipsychotic for patients with first-episode and chronic schizophrenia....
Blonanserin was developed in Japan in 2008 as an antipsychotic drug. ...Taken together, blonanserin may be a promising candida …
Evaluation of dopamine D(3) receptor occupancy by blonanserin using [(11)C]-(+)-PHNO in schizophrenia patients.
Sakayori T, Tateno A, Arakawa R, Kim WC, Okubo Y. Sakayori T, et al. Psychopharmacology (Berl). 2021 May;238(5):1343-1350. doi: 10.1007/s00213-020-05698-3. Epub 2020 Nov 12. Psychopharmacology (Berl). 2021. PMID: 33180175 Free PMC article.
However, there has been no study concerning the continued use of blonanserin. OBJECTIVES: We examined D(2) and D(3) receptor occupancies in patients with schizophrenia who had been treated with blonanserin. ...CONCLUSIONS: Our study confirmed that blonanserin …
However, there has been no study concerning the continued use of blonanserin. OBJECTIVES: We examined D(2) and D(3) receptor occupanc …
Efficacy and safety of blonanserin versus risperidone in the treatment of schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
Deng SW, Xu Q, Jiang WL, Hong B, Li BH, Sun DW, Yang HB. Deng SW, et al. BMC Psychiatry. 2023 Oct 11;23(1):740. doi: 10.1186/s12888-023-05240-7. BMC Psychiatry. 2023. PMID: 37821875 Free PMC article.
CONCLUSION: The efficacy of blonanserin is similar to that of risperidone, but it is unclear whether blonanserin is more effective than risperidone at improving cognitive and social function. More high-quality studies are needed to verify the efficacy and safety of …
CONCLUSION: The efficacy of blonanserin is similar to that of risperidone, but it is unclear whether blonanserin is more effec …
201 results